stockrowGSK PLC Sponsored ADR
GSK Healthcare Drug Manufacturers General
GSK PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $43.1 billion, up 7.44% from fiscal 2024.
- Revenue
- +3.75%
- EPS
- −14.7%
- Free cash flow
- +62.4%
- Total debt
- +33.2%
Quarter to September 2026, against a year earlier
Follow GSK
Alert me
GSK PLC Sponsored ADR (GSK) Free cash flow
GSK PLC Sponsored ADR's free cash flow for fiscal 2025 was $6.5B, up 34.1% from $4.8B in fiscal 2024. Over the twelve months to 30 September 2026 it was $8.8B. Over the past ten years it has ranged from $1.5B (fiscal 2015) to $9.7B (fiscal 2020); the current reading is higher than 45% of that period. GSK PLC Sponsored ADR ranks 11th of 21 Drug Manufacturers General companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $6.5B | 34.06% |
| FY2024 | $4.8B | (13.28%) |
| FY2023 | $5.6B | (18.18%) |
| FY2022 | $6.8B | (16.85%) |
| FY2021 | $8.2B | (15.52%) |
| FY2020 | $9.7B | 19.05% |
| FY2019 | $8.1B | (13.74%) |
| FY2018 | $9.4B | 44.71% |
| FY2017 | $6.5B | 6.00% |
| FY2016 | $6.1B | 311.05% |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $3.1B | (1.66%) |
| Jun 2026 | $3.1B | 194.85% |
| Mar 2026 | $1.1B | (32.35%) |
| Dec 2025 | $1.6B | (17.20%) |
| 43 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| SNY Sanofi compare | $23.8B |
| GILD Gilead Sciences, Inc. compare | $13.8B |
| PFE Pfizer Inc. compare | $11.8B |
| AMGN Amgen Inc. compare | $9.6B |
| BMY Bristol Myers Squibb Company compare | $9.3B |
| GSK GSK PLC Sponsored ADR | $8.8B |
| NVO Novo Nordisk A/S compare | $7.6B |
| AZN AstraZeneca PLC compare | $6.3B |
| BIIB Biogen Inc. compare | $1.7B |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on GSK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement